Combined bowel-liver transplantation in an infant with microvillous inclusion disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 22, Issue 4, 1996, Pages 405-408

  Herzog, D ^a   Atkison, P ^b   Grant, D ^b   Paradis, K ^a   Williams, S ^b   Seidman, E ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE REPORT; HUMAN; INFANT; INFANTILE DIARRHEA; INFECTION RISK; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

BIOPSY; DIARRHEA, INFANTILE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINES; LIVER TRANSPLANTATION; MALE; MICROSCOPY, ELECTRON; MICROVILLI; PARENTERAL NUTRITION, TOTAL; TACROLIMUS;

EID: 0030007433     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199605000-00013     Document Type: Article

References (21)

1. Phillips AD. Familial microvillous atrophy: a clinicopathological survey of 23 cases. J Pediatr Gastroenterol Nutr 1992;14:380-96.
2. Cutz E. Microvillous inclusion disease: an inherited defect of brush-border assembly and differentiation. N Engl J Med 1989;320:646-51.
3. Russo P, Jespers S, Baehler P, D'Agata I, Seldman E. Intractable diarrhea of early infancy: a 20 year review at the Hôpital Sainte-Justine. Lab Invest 1995;72:7p (abstract 35).
4. Couper RTL, Berzen A, Berall G, Sherman PM. Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillous atrophy. Gut 1989;20:1020-4.
5. Todo S. Clinical intestinal transplantation. Transplant Proc 1993;25:2195-7.
6. Goulet O. Which patients need small bowel transplantation for neonatal short bowel syndrome? Transplant Proc 1992; 24:1058-9.
7. Wallander J. Extreme short bowel syndrome in neonates: an indication for small bowel transplantation? Transplant Proc 1992;24:1230-5.
8. Oliva MM, Perman JA. Saavedra JM, Young-Ramsaran J, Schwarz KB. Successful intestinal transplantation for microvillous inclusion disease. Gastroenterology 1994;106: 771-4.
9. Hoffman AL. The use of FK506 for small intestinal allotransplantation. Transplantation 1990;49:483-90.
10. Bumgardner GL. New immunosuppressive agents. Gastroenterol Clin North Am 1993;2:421-31.
11. Alessiani M. Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 1993;25:628-34.
12. Starzl TE. FK506 versus cyclosporine. Transplant Proc 1993;25:511-2.
13. Tzakis AG. Two-year experience with FK506 in pediatric patients. Transplant Proc 1993;25:619-21.
14. McDiarmid SV. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993;55:1328-32.
15. Textor SC. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55:1332-9.
16. Armitage JM. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppression. J Thorac Cardiovasc Surg 1993;3:464-73.
17. Abu Elgmad K. Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc 1993;25: 1202-3.
18. Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy in paediatric transplant patients treated with FK506. Lancet 1995;345:894-6.
19. Gunji Y. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK506, rapamycin, or RS-61443. Transplant Proc 1993;25:752-3.
20. Shibata T. Does FK506 accelerate the development of coronary artery disease in the transplant heart as well as in the native heart?. Transplant Proc 1993;25:1145-8.
21. Noto S, Fujiwara H, Ban T, Ohara K. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. Transplant Proc 1994;26:855-7.